title: Time to tune the treatment of Ph+ ALL.
abstract: In this issue of Blood, Chalandon et al report the results of a prospective randomized study comparing standard vs less-intensive chemotherapy, both combined with imatinib, for patients with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). They show that the less-intensive therapy reduces early mortality without impairing efficacy, resulting in a significantly higher hematologic complete remission (CR) rate and an equivalent major molecular response (MMolR) rate.
authors.affiliation: FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE.
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Yanada
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines